Authors:
Shulman, NS
Machekano, RA
Shafer, RW
Winters, MA
Zolopa, AR
Liou, SH
Hughes, M
Katzenstein, DA
Citation: Ns. Shulman et al., Genotypic correlates of a virologic response to stavudine after zidovudinemonotherapy, J ACQ IMM D, 27(4), 2001, pp. 377-380
Citation: Ma. Winters et Tc. Merigan, Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nucleoside analogs, ANTIM AG CH, 45(8), 2001, pp. 2276-2279
Authors:
Kim, EY
Winters, MA
Kagan, RM
Merigan, TC
Citation: Ey. Kim et al., Functional correlates of insertion mutations in the protease gene of humanimmunodeficiency virus type 1 isolates from patients, J VIROLOGY, 75(22), 2001, pp. 11227-11233
Authors:
Winters, MA
Baxter, JD
Mayers, DL
Wentworth, DN
Hoover, ML
Neaton, JD
Merigan, TC
Citation: Ma. Winters et al., Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens, ANTIVIR TH, 5(1), 2000, pp. 57-63
Authors:
Baxter, JD
Mayers, DL
Wentworth, DN
Neaton, JD
Hoover, ML
Winters, MA
Mannheimer, SB
Thompson, MA
Abrams, DI
Brizz, BJ
Ioannidis, JPA
Merigan, TC
Citation: Jd. Baxter et al., A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy, AIDS, 14(9), 2000, pp. F83-F93
Authors:
Shafer, RW
Warford, A
Winters, MA
Gonzales, MJ
Citation: Rw. Shafer et al., Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1-infected individuals, J VIROL MET, 86(2), 2000, pp. 143-153
Authors:
Winters, MA
Coolley, KL
Cheng, P
Girard, YA
Hamdan, H
Kovari, LC
Merigan, TC
Citation: Ma. Winters et al., Genotypic, phenotypic, and modeling studies of a deletion in the beta 3-beta 4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors, J VIROLOGY, 74(22), 2000, pp. 10707-10713
Authors:
Schapiro, JM
Winters, MA
Lawrence, J
Merigan, TC
Citation: Jm. Schapiro et al., Clinical cross-resistance between the HIV-1 protease inhibitors saquinavirand indinavir and correlations with genotypic mutations, AIDS, 13(3), 1999, pp. 359-365
Authors:
Schapiro, JM
Lawrence, J
Speck, R
Winters, MA
Efron, B
Coombs, RW
Collier, AC
Merigan, TC
Citation: Jm. Schapiro et al., Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS Clinical Trials Group 229, J INFEC DIS, 179(1), 1999, pp. 249-253
Authors:
Gray, CM
Lawrence, J
Schapiro, JM
Altman, JD
Winters, MA
Crompton, M
Loi, M
Kundu, SK
Davis, MM
Merigan, TC
Citation: Cm. Gray et al., Frequency of class I HLA-restricted anti-HIV CD8(+) T cells in individualsreceiving highly active antiretroviral therapy (HAART), J IMMUNOL, 162(3), 1999, pp. 1780-1788
Authors:
Shafer, RW
Winters, MA
Palmer, S
Merigan, TC
Citation: Rw. Shafer et al., Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients (vol 128, pg 906, 1998), ANN INT MED, 129(12), 1998, pp. 1083-1083